Etranacogene dezaparvovec 100 tera genome copies/10ml solution for infusion vials
NHS hospitals in England used £114,400,000 of indicative cost of Etranacogene dezaparvovec 100 tera genome copies/10ml solution for infusion vials in the 12 months to July 2026, about 0.4% of all hospital medicines spend. That is up 0.0% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Etranacogene dezaparvovec 100 tera genome copies/10ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Etranacogene dezaparvovec 100 tera genome copies/10ml solution for infusion vials most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Royal Free London Nhs Foundation Trust | £98,800,000 |
| Oxford University Hospitals Nhs Ft | £5,200,000 |
| Leeds Teaching Hpls Nhs Trust | £2,600,000 |
| Guy's & St Thomas' Nhs Foundation Trust | £2,600,000 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.